IL93576A - Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressants - Google Patents

Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressants

Info

Publication number
IL93576A
IL93576A IL9357690A IL9357690A IL93576A IL 93576 A IL93576 A IL 93576A IL 9357690 A IL9357690 A IL 9357690A IL 9357690 A IL9357690 A IL 9357690A IL 93576 A IL93576 A IL 93576A
Authority
IL
Israel
Prior art keywords
tetrahydro
naphthalenamine
cis
inflammation
psychosis
Prior art date
Application number
IL9357690A
Other languages
English (en)
Hebrew (he)
Other versions
IL93576A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23244506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL93576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of IL93576A0 publication Critical patent/IL93576A0/xx
Publication of IL93576A publication Critical patent/IL93576A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL9357690A 1989-03-07 1990-02-28 Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressants IL93576A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/320,014 US4981870A (en) 1989-03-07 1989-03-07 Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Publications (2)

Publication Number Publication Date
IL93576A0 IL93576A0 (en) 1990-11-29
IL93576A true IL93576A (en) 1995-12-08

Family

ID=23244506

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9357690A IL93576A (en) 1989-03-07 1990-02-28 Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressants

Country Status (17)

Country Link
US (2) US4981870A (da)
EP (1) EP0386997B1 (da)
JP (2) JPH0714870B2 (da)
KR (1) KR920005810B1 (da)
AT (1) ATE150299T1 (da)
AU (1) AU610036B2 (da)
CA (1) CA2011428C (da)
DE (1) DE69030212T2 (da)
DK (1) DK0386997T3 (da)
HU (1) HU221624B1 (da)
IE (1) IE81047B1 (da)
IL (1) IL93576A (da)
MY (1) MY106272A (da)
NZ (1) NZ232800A (da)
PH (1) PH26542A (da)
PT (1) PT93351B (da)
ZA (1) ZA901743B (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
WO1991009594A1 (en) * 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
CA2166100A1 (en) * 1993-06-23 1995-01-05 Richard A. Glennon Sigma receptor ligands and the use thereof
ES2074946B1 (es) * 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
SK180499A3 (en) 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
JP2003518487A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク ヒドロゲル駆動型積層薬物製剤
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US6988556B2 (en) * 2002-02-19 2006-01-24 Halliburton Energy Services, Inc. Deep set safety valve
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
JP4610336B2 (ja) * 2002-09-16 2011-01-12 セプラコール インク． トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療
CA2498175A1 (en) * 2002-09-16 2004-03-25 Sepracor Inc. Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CZ2006427A3 (cs) * 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
MX2008000250A (es) * 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
KR101381768B1 (ko) * 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
CA2636324C (en) * 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
ES2643602T3 (es) 2006-03-31 2017-11-23 Sunovion Pharmaceuticals Inc. Aminas y quirales
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2008152404A (ru) * 2006-05-31 2010-07-10 Сепракор Инк. (Us) Лечение болевых расстройств транс 4-(3, 4-дихлорфенил)-1, 2, 3, 4-тетрагидро-1-нафталинамином и его формамидом
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
EP2074092A2 (en) * 2007-01-18 2009-07-01 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CN103936605B (zh) 2007-05-31 2017-09-01 赛诺维信制药公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
AU2015259346A1 (en) * 2014-05-13 2016-12-08 Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of ADHD
MX2016014780A (es) * 2014-05-13 2017-07-25 Sunovion Pharmaceuticals Inc Metodos y composiciones de dasotralina para el tratamiento del adhd.
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
FR3071726B1 (fr) * 2017-09-29 2020-09-04 Univ Paris Sud Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420472A (en) * 1972-09-27 1976-01-07 Pfizer Aminophenyltetralin compounds
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Also Published As

Publication number Publication date
MY106272A (en) 1995-04-29
AU5079690A (en) 1990-09-20
PT93351A (pt) 1990-11-07
KR920005810B1 (ko) 1992-07-20
DE69030212D1 (de) 1997-04-24
JPH0714870B2 (ja) 1995-02-22
HUT59000A (en) 1992-04-28
PH26542A (en) 1992-08-19
ATE150299T1 (de) 1997-04-15
CA2011428A1 (en) 1990-09-07
EP0386997A2 (en) 1990-09-12
US4981870A (en) 1991-01-01
DE69030212T2 (de) 1997-06-26
IE900798L (en) 1990-09-07
KR900013949A (ko) 1990-10-22
EP0386997B1 (en) 1997-03-19
JPH02300121A (ja) 1990-12-12
ZA901743B (en) 1991-10-30
HU901325D0 (en) 1990-05-28
PT93351B (pt) 1996-03-29
HU221624B1 (hu) 2002-12-28
DK0386997T3 (da) 1997-04-14
AU610036B2 (en) 1991-05-09
IE81047B1 (en) 1999-12-01
US5061728A (en) 1991-10-29
NZ232800A (en) 1997-07-27
JPH07173056A (ja) 1995-07-11
JP3020808B2 (ja) 2000-03-15
CA2011428C (en) 1994-11-08
EP0386997A3 (en) 1992-04-29
IL93576A0 (en) 1990-11-29

Similar Documents

Publication Publication Date Title
US5061728A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of inflammation and as immunosuppressants
US10188613B2 (en) Exo-S-mecamylamine formulation and use in treatment
KR100412154B1 (ko) N-프로파길-1-아미노인단의r-에난시오머,염,및그들의조성물의사용
DE69233462T2 (de) Zusammensetzung die Tramadol und ein nichtsteroides entzündungshemmenden Mittel enthält
CS227019B2 (en) Method of preparing (-)-n-methyl-3-(2-methylphenyloxy)-3-phenylpropylamine
JP2014051528A (ja) エキソ−ｓ−メカミラミン製剤および治療におけるその使用
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
EP0647134A1 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
SK13862001A3 (sk) Použitie zlúčeniny pri výrobe liečivá na liečenie neurologických alebo neuropsychiatrických porúch
CA2139000A1 (en) Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
Korsgaard et al. The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New β-Aminobutyric Acid Agonist
AU608922B2 (en) Method for the treatment of anxiety
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
WO2003002059A2 (en) Tolterodine metabolites
US6552087B1 (en) Therapeutic agent comprising (+)-sibutramine
Wei et al. Stereoselective disposition of hydroxychloroquine and its metabolites in rats
CA2168265C (en) Antidepressant
DK174506B1 (da) Anvendelse af en forbindelse til fremstilling af et farmaceutisk præparat til behandling af fibromyalgia
US4053637A (en) Compounds of diphenylcyclopentylamine type and methods for their uses
US4141993A (en) Compounds of diphenylcyclopentylamine type and methods for their preparation
SK19997A3 (en) Use of selegilin in the treatment of epilectic conditions and pharmaceutical composition containing same
DE3686538T2 (de) Verwendung von dibenz(cd,f)indol-derivaten zur praevention vom alkoholmissbrauch.
US3772440A (en) Method for the treatment of parkinsonism and depression
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
Wong et al. DEVELOPMENT OF ANTIDEPRESSANT DRUGS

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees
MM9K Patent not in force due to non-payment of renewal fees